INVESTORS
We operate with trust and do the right thing
News
-
DEC 12 2019NewsYuhan to start phase-3 trial on lung cancer drug LazertinibYuhan Corp. said it would start a phase-3 global study to evaluate the efficacy of Lazertinib (YH25448) as the first-line treatment for non-small cell lung cancer (NSCLC)
-
JUN 3 2019NewsY-biologics, Genosco ink deal for cancer immunotherapy combosY-biologics Inc., a South Korean biopharmaceutical firm, and U.S.-based biotechnology venture Genosco Inc. have recently signed a contract for cancer drugs research and development
-
NOV 5 2018NewsYuhan signs $1.25b licensing deal with JanssenSouth Korean pharmaceutical giant Yuhan announced Monday that it had licensed out its new clinical-stage lung cancer drug to Janssen Biotech in a deal potentially valued at up to $1.25 billion
